Key Points
- Four stages: a safe scribe for one clinic; one record across doctor, desk, pharmacy and patient; checks that prevent harm; and, with consent and ethics approval, research that makes Indian medicine safer.
- Each stage starts only when the one before is measured on real patients, not when it is built.
- The long-term aim is a health research and development company built on India's own clinical data: Indian languages, every system of medicine, and Indian patients.
- Patient data is never sold. Research uses only consented, de-identified data, under ethics review, with results published.
The Four Stages
- 1ScribeThe doctor talks; a verified note and prescription are signed
- 2Shared recordDesk, pharmacy, patient and family on one consented record
- 3PreventionChecks that catch harm before it happens
- 4ResearchConsented data that answers questions no one in India can answer today
Stage 1 and 2: Scribe and Shared Record
| Feature | What it does | Gate before release |
|---|---|---|
| Doctor app pilot | Listen, draft, verify, sign, prescription PDF | Consent at the desk; legal and ethics review; zero invented medicines on real voices |
| Verified doctors | Doctors verified against India's national registry of healthcare professionals[1] | Registry integration tested |
| Desk app | Registration, ABHA link, consent, vitals, weight for children | Consent text reviewed by counsel |
| Pharmacy app | Receives the signed prescription and allergy flags; records what was dispensed | Pharmacist field test |
| Patient and family app | Visit summaries in the patient's language, reminders, family record, emergency card | Guardian consent for children's records[2] |
| ABDM exchange | Share records with other providers through ABDM with the patient's consent | ABDM sandbox certification |
Stage 3: Prevention Features
| Feature | The harm it targets |
|---|---|
| Medicine list across all systems | Duplicates and interactions between modern, Ayurvedic and homeopathic medicines the doctor never hears about |
| Weight-based dose checks for children | Dosing errors, the most common cause of potentially harmful errors in children[3] |
| Pregnancy checks | Medicines unsafe in pregnancy given to a woman who may be pregnant |
| Antibiotic stewardship prompts | Overuse of WHO "Watch" antibiotics, over half of doses in India[4] |
| Banned-combination checks | Irrational fixed-dose combinations |
| Chronic-care follow-up | Missed refills and checks for diabetes and high blood pressure |
| Family screening prompts | Relatives of a patient with an inherited condition never offered testing (with consent and counselling) |
| 3D scan viewer | Patients who cannot understand their own CT or MRI (from the imaging project on the home page) |
Checks that influence a clinical decision may make 1Heath regulated medical device software. Each one will be assessed against CDSCO's guidance before release[5].
Stage 4: A Health Research Company
About half of Indians use AYUSH or home remedies[6], yet no record anywhere holds what one patient takes from every system at once, so questions about combined use and harm are hard to study. A signed, structured, consented record across every system of medicine makes them answerable.
| Research programme | Question it answers | Partner type |
|---|---|---|
| Medicine safety signals | Which combinations, including Ayurvedic and modern medicines, are followed by harm? | National pharmacovigilance programmes, including the AYUSH programme[7] |
| Indian clinical language | How do Indian doctors and patients describe illness and medicines across languages? | Universities, speech and language researchers |
| Antibiotic use | Where and why are broad-spectrum antibiotics prescribed, and does prompting change it? | Public-health researchers; India has no formal surveillance of antibiotic use[4] |
| Real-world outcomes | How do Indian patients respond to common treatments outside trials? | Medical colleges, government research programmes such as PRIP[8] |
| Trial recruitment | Can patients who opt in be told about trials they qualify for? | Hospitals and sponsors, with ethics approval |
Research Rules
- 1
Separate, explicit consent for research, never bundled with care. Refusing changes nothing about the patient's care.
- 2
De-identified data in a controlled environment; no raw records leave it.
- 3
Independent ethics review of every study, and a data-access committee that includes doctors and patients.
- 4
Results published, including negative ones.
- 5
Never sold. Partners fund studies; they never buy data.
Our Own Models
Speech and drafting are 1Heath's largest cost per consultation (see the business model). Training India-hosted speech and drafting models on consented, de-identified consultations would cut that cost, keep data in India, and improve accuracy on code-mixed Indian speech. This begins only after the consent and research rules above are in force.
Sources
- National Health Authority. ABDM Insights public dashboard, figures last updated 5 November 2026, 8:33 PM. dashboard.abdm.gov.in
- Digital Personal Data Protection Rules, 2025, Rule 10: verifiable consent for processing personal data of a child. dpdpa.com
- Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA, 2001. scispace.com
- Consumption of systemic antibiotics in India in 2019. Lancet Regional Health Southeast Asia, 2022, as reported by Down To Earth. downtoearth.org.in
- Nishith Desai Associates. From code to compliance: decoding India's medical device software guidance (CDSCO guidance of 21 July 2026). nishithdesai.com
- Ministry of Statistics and Programme Implementation. Press note: Survey on Ayush, NSS 79th round (July 2022 to June 2023), 13 June 2024. mospi.gov.in
- ThePrint. 65,000 misleading ads flagged, 3,000 adverse reactions recorded since 2018, says Ayush Secretary, 9 March 2026. theprint.in
- Medical Dialogues. DoP notifies Rs 5,000 crore PRIP scheme to boost pharma and MedTech R&D, 4 October 2025. medicaldialogues.in